Review Finds No Causal Link Between Prenatal Tylenol
A major review of over 3 million participants finds higher-quality evidence does not support a causal link between prenatal acetaminophen use and
A new scientific review has found no causal link between taking acetaminophen during pregnancy and neurodevelopmental disorders in children. The analysis, published in September 2026 in the journal Developmental Medicine & Child Neurology, challenges previous studies that suggested a connection.
Various studies over the years have linked prenatal use of the common pain reliever, also known as paracetamol or Tylenol, with conditions like autism spectrum disorder and attention-deficit/hyperactivity disorder. Many of those studies were small, poorly designed, or found only weak associations. This latest review aimed to assess the totality of the evidence.
The Umbrella Review Findings
The researchers conducted an umbrella review, which synthesizes data from multiple meta-analyses. They included seven meta-analyses encompassing more than 3 million total participants. When the team looked at all the studies without restriction, they observed small positive associations between prenatal acetaminophen exposure and both autism and ADHD.
However, the picture changed dramatically when the analysis focused on higher-quality research. After restricting assessments to the better-designed meta-analyses and individual studies, the effect estimates were substantially weakened and approached zero. The review concluded there is no robust epidemiological evidence to support a causal association.
A Call for Evidence-Based Decisions
First author Hoda Tayebi Hillali, DDS, MSc, of the University of Santiago de Compostela in Spain, emphasized the need for robust evidence on widely debated questions. "Our findings show that the apparent association between prenatal paracetamol exposure and autism or ADHD weakens as methodological quality improves," Hillali said. This challenges the interpretation of a causal link and supports evidence-based decisions during pregnancy.
The review's methodology highlights a critical issue in medical research: lower-quality studies can produce misleading signals. The authors argue that headlines often outpace the science, creating anxiety for pregnant individuals. This comprehensive analysis provides a clearer, more reliable picture by prioritizing rigorous study design.
For pregnant women managing pain or fever, this review offers significant reassurance. The findings suggest that concerns based on earlier, less robust research may have been overstated. The study shows the importance of consulting healthcare providers to weigh the benefits and risks of any medication during pregnancy, using the best available evidence.
